PDF(Pubmed)
Abstract：
BACKGROUND: Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) is an inflammatory disease, which can significantly impair visual acuity if not adequately treated. Fluocinolone-acetonide sustained-release-0.2 µg/day intravitreal (FAc) implants are indicated for prevention of relapse in recurrent NIU-PS. The aim here was to provide treating clinicians with some consensus-based-recommendations for the clinical management of patients with NIU-PS with 0.2 µg/day FAc implants.
METHODS: A European-clinical-expert-group agreed to develop a consensus report on different issues related to the use of FAc implants in patients with NIU-PS.
RESULTS: The Clinical-expert-panel provided specific recommendations focusing on clinical presentation (unilateral/bilateral) of the NIU-PS; systemic involvement of NIU-PS and the lens status. Treatment algorithms were developed; one that refers to the management of patients with NIU-PS in clinical practice and another that establishes the best clinical scenarios for the use of FAc implants, both as monotherapy and as adjuvant therapy. Additionally, the Clinical-expert-panel has provided recommendations about the use of the FAc implants in a clinical-setting. The Clinical-expert-panel also considered the safety profile of FAc implants and their possible implications in the daily practice.
CONCLUSIONS: As more clinical experience has been gained using FAc implants, it was necessary to update the clinical recommendations that guide patient management in the clinic. The current consensus document addresses relevant issues related to the use of FAc implants on different types of patients with various etiologies of NIU-PS, and was conducted to standardize approaches to help specialists obtain better clinical outcomes.
METHODS: A European-clinical-expert-group agreed to develop a consensus report on different issues related to the use of FAc implants in patients with NIU-PS.
RESULTS: The Clinical-expert-panel provided specific recommendations focusing on clinical presentation (unilateral/bilateral) of the NIU-PS; systemic involvement of NIU-PS and the lens status. Treatment algorithms were developed; one that refers to the management of patients with NIU-PS in clinical practice and another that establishes the best clinical scenarios for the use of FAc implants, both as monotherapy and as adjuvant therapy. Additionally, the Clinical-expert-panel has provided recommendations about the use of the FAc implants in a clinical-setting. The Clinical-expert-panel also considered the safety profile of FAc implants and their possible implications in the daily practice.
CONCLUSIONS: As more clinical experience has been gained using FAc implants, it was necessary to update the clinical recommendations that guide patient management in the clinic. The current consensus document addresses relevant issues related to the use of FAc implants on different types of patients with various etiologies of NIU-PS, and was conducted to standardize approaches to help specialists obtain better clinical outcomes.
摘要：
背景：影响眼睛后段的非感染性葡萄膜炎（NIU-PS）是一种炎症性疾病，如果不充分治疗，可能会严重损害视力。氟轻松-丙酮持续释放-0.2µg/天玻璃体内（FAc）植入物可用于预防复发性NIU-PS的复发。这里的目的是为临床医生提供一些基于共识的建议，用于使用0.2µg/天FAc植入物的NIU-PS患者的临床管理。
方法：一个欧洲临床专家组同意就NIU-PS患者使用FAc植入物的不同问题制定一份共识报告。
结果：临床专家小组针对NIU-PS的临床表现（单侧/双侧）；NIU-PS的全身受累和晶状体状态提供了具体建议。开发了治疗算法;一个是指在临床实践中对NIU-PS患者的管理，另一个是建立使用FAc植入物的最佳临床方案，作为单一疗法和辅助疗法。此外,临床专家小组提供了有关在临床中使用FAc植入物的建议.临床专家小组还考虑了FAc植入物的安全性及其在日常实践中的可能影响。
结论：随着使用FAc植入物获得更多临床经验，有必要更新指导临床患者管理的临床建议.当前的共识文件解决了与不同类型的NIU-PS病因不同的患者使用FAc植入物相关的问题，并进行了标准化方法，以帮助专家获得更好的临床结果。
方法：一个欧洲临床专家组同意就NIU-PS患者使用FAc植入物的不同问题制定一份共识报告。
结果：临床专家小组针对NIU-PS的临床表现（单侧/双侧）；NIU-PS的全身受累和晶状体状态提供了具体建议。开发了治疗算法;一个是指在临床实践中对NIU-PS患者的管理，另一个是建立使用FAc植入物的最佳临床方案，作为单一疗法和辅助疗法。此外,临床专家小组提供了有关在临床中使用FAc植入物的建议.临床专家小组还考虑了FAc植入物的安全性及其在日常实践中的可能影响。
结论：随着使用FAc植入物获得更多临床经验，有必要更新指导临床患者管理的临床建议.当前的共识文件解决了与不同类型的NIU-PS病因不同的患者使用FAc植入物相关的问题，并进行了标准化方法，以帮助专家获得更好的临床结果。
